Engflag

Aflem

Quick links to important sections

Aflem

Aflem_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aflem

What is Aflem? Definition, Composition, and General Purpose

Property Description
Active Ingredient Carbocysteine (S-carboxymethyl-L-cysteine)
Dosage Form Syrup, hard capsules, granules, oral thin film
Pharmacological Class Mucoactive Agent (Mucolytic)
General Purpose To reduce the viscosity of thick, excessive mucus
Origin Synthetic derivative of L-cysteine

Defining Aflem: Type and Classification of the Medicine

Aflem is a medicinal preparation whose single active pharmaceutical ingredient is Carbocysteine, classified as a mucoactive agent for respiratory tract disorders. This compound is chemically defined as S-carboxymethyl-L-cysteine, which is a synthetic cysteine derivative. It is assigned the ATC code R05CB03, placing it within the specialized pharmacological class of mucolytics. Mucolytics are clinically recognized for their ability to modify the physical properties of mucus itself. Aflem is a single-ingredient product focused entirely on this core biochemical function.

Carbocysteine Composition and Available Forms

This monocomponent drug features Carbocysteine as the essential active substance. The medication is intended for oral administration and is typically manufactured in several dosage forms, including a liquid syrup, hard capsules, and granules designed to be dissolved into a solution. The syrup form is often used for patients who may have difficulty swallowing solid forms. The availability of multiple oral preparations ensures consistent delivery of the active ingredient across different patient needs.

General Purpose: What Aflem Is Designed to Help Achieve

The general purpose of Aflem is to address conditions characterized by overly viscous mucus by improving its fluidity and aiding clearance. The mucoactive properties of Carbocysteine involve regulating the internal structure of mucus. Carbocysteine facilitates the reduction of sputum viscosity in patients with respiratory disorders. This action helps thin and loosen the mucus, promoting enhanced mucus clearance from the airways and supporting a person's ability to breathe more easily when congested.

What side effects are possible with Aflem?

Possible Side Effects and Safety Information for Aflem

Official regulatory documents from major governmental health authorities contain no documented safety data, adverse event summaries, or required warnings specifically for a product named Aflem. Therefore, a comprehensive description of the side effects, frequency classifications, and safety profile is currently unavailable from authoritative sources.

Since this information is not explicitly detailed in publicly available regulatory records, the following points summarize the necessary structure for its eventual inclusion once official data is released:

Adverse Reaction Profile Structure

Category Regulatory Status (Aflem)
Common Adverse Reactions Not officially documented by regulatory bodies.
Serious Adverse Reactions No specific serious adverse events are documented.
System-Organ Classes Not defined. Common classes include Gastrointestinal, Nervous System, and Skin disorders.
Frequency Classification No frequency framework (e.g., Very Common, Rare) is established.

Safety Considerations

Official prescribing information for approved drugs typically outlines critical safety parameters. For Aflem, these details are currently absent from authoritative documentation, including:

  • Contraindications: Conditions or situations where the drug must not be used (e.g., known hypersensitivity).
  • Warnings and Precautions: Safety-related limitations or necessary monitoring for specific patient populations (e.g., pediatric, geriatric, or those with hepatic or renal impairment).
  • Drug Interactions: Specific substances that, when taken with Aflem, may alter the drug's effect or increase the risk of adverse reactions.

All medicinal products undergo pharmacovigilance, a system of monitoring for drug safety after they have been authorized for public use. Any new or serious adverse reactions are collected through spontaneous reporting systems and may result in updates to the product’s official labeling, ensuring the documented safety information reflects the current understanding of risk.

Overdose and Emergency Response

The official regulatory profile for Aflem (Carbocysteine) overdose is established by the expected clinical signs and the immediate required emergency actions.

Documented Overdose Manifestations

The most likely presentation of an acute overdosage event is gastrointestinal disturbance. Officially documented symptoms that may be experienced include nausea, vomiting, and stomach pains (gastralgia). This indicates that the primary physiological system affected by overexposure is the gastrointestinal system.

Mandated Emergency Action

Immediate medical attention must be sought when an overdosage is suspected or confirmed. Regulatory guidance states that a dose intake significantly exceeding the therapeutic recommendation—such as four to five times the advised level—warrants contacting the nearest hospital or doctor straight away. Individuals must seek immediate medical attention and are advised to take the medicine container or label with them to inform healthcare staff.

Official Management and Antidotal Status

Official regulatory documents specify that no specific antidote is known for Carbocysteine overdosage. Therefore, management is defined as symptomatic and supportive therapy. Procedural measures such as gastric lavage may be considered or may be beneficial, and subsequent patient monitoring and observation are required following any initial interventions. No population-specific overdose considerations are explicitly detailed in the official prescribing information.

Therapeutic Uses of Aflem

What Aflem Treats: Main Uses and Benefits

Aflem (Carbocysteine) is commonly used to help address respiratory conditions characterized by the overproduction of unusually thick and viscous mucus in the airways. The therapeutic role of Carbocysteine is aligned with symptom management in conditions such as Chronic Bronchitis, COPD, and acute episodes of bronchitis or rhinopharyngitis. The primary therapeutic benefit is relevant for easing symptoms related to physical discomfort, which supports the patient's ability to clear the chest.

Key Therapeutic Applications

This mucoactive agent is applied in addressing the persistent, significant sputum burden found in long-term conditions like COPD and Chronic Bronchitis, supporting patients in managing the chronic, often tiring productive cough. It is commonly used for symptomatic support during acute, short-term episodes where the sudden formation of highly viscous mucus leads to an ineffective cough.

“It may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.”

The medication is relevant in clinical situations, including Bronchiectasis, where symptoms linked to organ-specific functional stress are present, providing supportive benefit to patients of various age groups.

Quick Fact: Relief for Thick, Difficult-to-Clear Mucus

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

The eligibility for Aflem (Carbocysteine) is strictly defined by regulatory documents, which establish clear restrictions based on age, physiological status, and underlying medical conditions.

Population Status Regulatory Classification (Official Labeling)
Allowed Adults and children aged 2 years and older (varies by formulation)
Contraindicated Children less than 2 years of age
Contraindicated Patients with active peptic ulceration (gastric or duodenal)

Absolute Contraindications

The medicine is officially contraindicated and must not be used by any patient with active peptic ulceration or known hypersensitivity to the active substance or any specific excipients. Furthermore, the use of mucolytics in the pediatric population under 2 years old is an absolute contraindication specified by many national health authorities due to specific risk concerns.

Restricted and Conditional Use

Official prescribing information establishes conditional use for certain groups. Use is not recommended during the first trimester of pregnancy and while breastfeeding due to insufficient data regarding fetal and infant safety. Additionally, caution is advised for the elderly population and patients with a history of gastroduodenal ulcers, who require specific consideration as stated in the product's regulatory label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aflem's interaction profile is officially defined by key pharmacodynamic restrictions and specific cautions noted in regulatory documents, rather than common drug-metabolizing enzyme interactions.

Documented Pharmacodynamic and Substance Interactions

Classification Interacting Agents / Conditions Official Regulatory Constraint
Contraindicated Combination Antitussive medicinal products, medicines that dry secretions (e.g., anticholinergics). Combination is documented as irrational and should not be co-administered due to direct antagonism of the mucolytic action.
Use-with-Caution Combination Medicines known to cause gastrointestinal bleeding (e.g., NSAIDs, corticosteroids, antiplatelet agents). Caution is required due to a documented increase in the risk of gastrointestinal bleeding or ulceration.
Pharmacogenetic Factor Genetic polymorphism in sulfoxidation capacity. This internal factor is noted to potentially lead to increased systemic exposure of the Carbocysteine active compound.
Substance Consideration Herbal products and supplements. Regulatory sources document insufficient data to determine interaction effects; no specific guidance is available.

Population-Specific Interaction Notes

Specific caution regarding interaction risks is documented for elderly patients and individuals with a history of gastroduodenal ulcers when co-administered with medicines that increase the risk of GI bleeding. No mandatory dose-timing separation requirements for co-administered medicines are specified in official labeling.

Mechanism of Action

Mucin Quality Control via Enzyme Modulation

Aflem (Carbocysteine) operates primarily as a muco-regulator, acting intracellularly within respiratory epithelial cells. The mechanism centers on the modulation of glycosyltransferase enzymes, such as sialyltransferase, which construct mucin molecules. This molecular action shifts the mucin synthesis pathway to favor the production of less rigid Sialomucins over highly viscous Fucomucins, modifying the structural composition of the secreted material.

Secretion Rheology and Facilitation of Clearance

The resulting change in mucin composition fundamentally reduces the viscosity and elasticity of the secretions. This lower tenacity facilitates the ciliary-driven movement of secretions, making the mucus easier to move and expel and contributing to the movement and expulsion of secretions within the airways.

Complementary Anti-inflammatory Pathway Stabilization

Beyond its structural role, the mechanism includes a stabilizing effect on cellular signaling. Carbocysteine acts as a free-radical scavenger and suppresses inflammatory signaling pathways like NF-κB, thereby modulating inflammatory signaling pathways that influence the cellular processes of mucin secretion.

Dosage and Administration Information

Official Administration Guidelines

Aflem (Carbocysteine) is administered solely via the oral route and is available in multiple forms, including hard capsules and various liquid solutions such as syrup or dissolved granules. Standard protocols describe an administration structured into two dose phases for adults and older adults. The initial regimen typically involves a daily dosage of 2250 mg of carbocisteine, which is taken in divided doses over the course of the day, usually three times daily (t.d.s.).

This higher starting dose is maintained until a satisfactory response is obtained in the clinical setting, at which point the dose is reduced to a 1500 mg maintenance dose daily. This maintenance amount is also administered in divided doses, with frequency potentially adjusting to three or four times daily, depending on the specific formulation used.

For liquid dosage forms, accurate measurement is required, necessitating the use of the measuring device supplied with the product to ensure proper usage. Dosing for pediatric patients (where approved) follows a distinct protocol, calculated based on the child's body weight (e.g., 20 mg/kg per day) rather than a fixed milligram amount, and is also given in divided daily amounts. In certain clinical contexts, administration is described as being preferably without meals, establishing a high-level contextual instruction for proper intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aflem

Evidence for Use in Chronic Bronchitis and COPD

Research in chronic respiratory disorders utilizing Aflem has primarily involved long-term Randomized Controlled Trials (RCTs) and Meta-analyses in adults with COPD or Chronic Bronchitis. Studies monitored the rate and frequency of acute exacerbations and health-related quality of life. Studies reported measurements of changes in the frequency of acute episodes compared to control groups. However, certainty remains low regarding the long-term effects on physiological markers, as findings related to objective lung function markers are often mixed or inconsistent. Research exploring mild-to-moderate COPD found no significant measured difference in exacerbation rate.

Evidence for Use in Acute Respiratory Tract Symptoms

Aflem was studied for its role in managing symptoms during acute, short-term respiratory conditions in adults and children. These were short-term clinical studies where the main outcomes examined were patient-reported outcomes like changes in cough severity and perceived ease of sputum clearance. The findings describe short-term patterns of symptom evolution. The certainty remains low compared to chronic studies, as much of the evidence is derived from older research, and follow-up durations are limited to the acute illness period.

Evidence for Use in Bronchiectasis

Dedicated long-term RCTs explored Aflem in adults with non-cystic fibrosis Bronchiectasis, monitoring the incidence of pulmonary exacerbations over one year. Recent research indicates that findings were mixed; studies reported no statistically significant difference in the primary outcome of reducing exacerbations compared to control groups. The findings were not sufficient to demonstrate a difference, and major clinical guidelines reflect that evidence is insufficient regarding a sustained impact.

Long-Term Evidence and Scientific Uncertainty

The most extensive research involves long-term trials for chronic conditions, with some follow-up lasting up to one year or more. However, long-term effects are not fully established related to physiological measures. Furthermore, data for certain groups remain insufficient (e.g., in Bronchiectasis), and findings were mixed or inconsistent regarding a measurable difference in lung capacity or airflow restriction over time.

Frequently Asked Questions (FAQ)

Common questions about Aflem (FAQ)

Q: What is Aflem used for?

A: Aflem is primarily used to treat Type 2 Diabetes Mellitus in adults. It works by helping the body lower high blood sugar (glucose) levels. It is often prescribed as an addition to diet and exercise when those measures alone are not enough to manage blood sugar. It can be used alone or in combination with other diabetes medications.

Q: How does Aflem work to treat diabetes?

A: Aflem belongs to a class of medicines called SGLT2 inhibitors. These medicines work in the kidneys to block a protein called the sodium-glucose cotransporter 2 (SGLT2). By blocking SGLT2, Aflem reduces the amount of glucose reabsorbed into the bloodstream, increasing the amount of glucose that is passed out of the body in the urine. This action helps to lower blood glucose levels.

Q: What are the potential side effects of taking Aflem?

A: Common side effects of Aflem can include genital yeast infections, urinary tract infections (UTIs), and increased urination. Less common, but serious, side effects include diabetic ketoacidosis (DKA), especially when blood sugar levels are only moderately high, and kidney problems. Due to the way it works, Aflem can also increase the risk of dehydration and low blood pressure. Patients should be aware of these risks and discuss any concerns with a healthcare provider.

Q: Can Aflem be taken with other diabetes medications?

A: Yes, Aflem is often used in combination with other medications for Type 2 Diabetes, such as metformin or insulin. When used with other glucose-lowering drugs, there may be an increased risk of hypoglycemia (low blood sugar). A healthcare provider will determine the appropriate combination and dosage based on individual patient needs and blood sugar control goals.

Q: What should I do if I miss a dose of Aflem?

A: If a dose of Aflem is missed, it should be taken as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. If you are unsure, it is best to consult your healthcare provider or pharmacist for guidance.

How should Aflem be stored and disposed of?

How to Store and Dispose of Aflem

Aflem (Carbocysteine) must be stored and handled according to official regulatory specifications to maintain its effectiveness and safety.

Storage Conditions

  • Temperature: Store at a temperature not exceeding 30 C (86 F). Do not refrigerate or freeze liquid forms.
  • Protection: Liquid formulations must be protected from light and stored in the original, tightly closed container to prevent moisture exposure.
  • In-Use Stability: Aflem syrup has a stability limit; once the bottle is opened, the medicine must be used within 3 months (90 days) and any unused portion must be discarded after this period.
  • Child Safety: The medication must be stored out of the sight and reach of children.

Disposal

Any unused or expired Aflem and its associated waste material must be disposed of in accordance with local requirements for pharmaceutical products, which typically means avoiding disposal into household trash or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPhilippines

Equivalent of Aflem found in:

A-Z Index: